Tom Stinchcombe

28PUBLICATIONS
134CO-AUTHORS
Molecular targetsEpidemiological modellingCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Radiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Jul 03, 2026
Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 Study.

|Jan 21, 2026
Prevalence and Clinical Characteristics of Germline Epidermal Growth Factor Receptor Mutations in the Southeastern Unites States.

Jenny O'Brien, Ryne C Ramaker, Ashley Moyer

|Jan 13, 2026
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.

Kristin A Higgins, Chen Hu, Helen J Ross

|Oct 23, 2025
A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer.

Hirva Mamdani, Ryan D Gentzler, Lin Gu

|Aug 11, 2025
Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results.

Ecaterina E Dumbrava, Thomas E Stinchcombe, Mrinal Gounder

|Jan 17, 2025
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.

Alicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno

Pageof 5

Frequent Collaborators

3 joint publications

Jeffrey D Bradley

2 joint publications

Suresh S Ramalingam

2 joint publications

Robert G Maki

2 joint publications

Tanios Bekaii-Saab